Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2-(4-((2-oxocyclohexylidene)methyl)phenyl)propionic Acid
2. 2-ocmpp
3. Cs 670
4. Cs-670
1. 69956-77-0
2. Pelubiprofen [inn]
3. Rs-2131
4. Cs-670
5. 2-[4-[(e)-(2-oxocyclohexylidene)methyl]phenyl]propanoic Acid
6. 1619c79fvj
7. Ncgc00183010-01
8. 2-ocmpp
9. Unii-1619c79fvj
10. Cs 670
11. Pelubiprofen (jan/inn)
12. Pelubiprofen [jan]
13. Dsstox_cid_28721
14. Dsstox_rid_82990
15. Dsstox_gsid_48795
16. Dw330sr
17. Chembl69308
18. Pelubiprofen [who-dd]
19. Schembl188062
20. Dw-330sr
21. Gtpl9876
22. Dtxsid2048795
23. (+-)-p-(((e)-2-oxocyclohexylidene)methyl)hydratropic Acid
24. Tox21_113272
25. Db12150
26. Compound 13b [pmid: 6607354]
27. Hy-12383
28. Cas-69956-77-0
29. Cs-0011235
30. D01865
31. Q27251763
32. (e)-2-[4-[(2-oxocyclohexylidene)methyl]phenyl]propanoic Acid
33. Benzeneacetic Acid, Alpha-methyl-4-((2-oxocyclohexylidene)methyl)-
34. [r,(?)]-2-[4-[((e)-2-oxocyclohexylidene)methyl]phenyl]propionic Acid
35. [s,(+)]-2-[4-[((e)-2-oxocyclohexylidene)methyl]phenyl]propionic Acid
36. Benzeneacetic Acid, .alpha.-methyl-4-((2-oxocyclohexylidene)methyl)-, (e)-
Molecular Weight | 258.31 g/mol |
---|---|
Molecular Formula | C16H18O3 |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 258.125594432 g/mol |
Monoisotopic Mass | 258.125594432 g/mol |
Topological Polar Surface Area | 54.4 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 376 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2021-03-16
Registration Number : Su289-7-ND
Manufacturer Name : Hunan Jiudian Hongyang Pharm...
Manufacturer Address : Tongguan Circular Economy Industrial base, WangCheng Economic and Technological Devel...
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2021-10-28
Registration Number : 1673-46-ND
Manufacturer Name : Kyungbo Pharmaceutical Co., ...
Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do
Registrant Name : MFC Corporation
Registration Date : 2020-12-03
Registration Number : 346-3-ND
Manufacturer Name : MFC Corporation
Manufacturer Address : 35 Cheongwon Industrial Complex 7-gil, Mado-myeon, Hwaseong-si, Gyeonggi-do
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2006-12-28
Registration Number : 711-1-ND
Manufacturer Name : Samoh Pharmaceutical Co., Lt...
Manufacturer Address : (429-852) 63, Okgucheonseo-ro 81beon-gil, Siheung-si, Gyeonggi-do
Registrant Name : Engichem Life Sciences Co., Ltd.
Registration Date : 2023-01-06
Registration Number : 238-9-ND
Manufacturer Name : Engichem Life Sciences Co., ...
Manufacturer Address : 59 Biovalley-ro, Jecheon-si, Chungcheongbuk-do
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2020
Lead Product(s) : Pelubiprofen,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2020
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2019
Lead Product(s) : Pelubiprofen,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2019
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Eperisone Hydrochloride
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 07, 2018
Lead Product(s) : Pelubiprofen,Eperisone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2018
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Aceclofenac
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2016
Lead Product(s) : Pelubiprofen,Aceclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2016
Details:
Undisclosed
Lead Product(s): Pelubiprofen,DW1030,DW340
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2015
Lead Product(s) : Pelubiprofen,DW1030,DW340
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 05, 2015
Details:
Undisclosed
Lead Product(s): Pelubiprofen,DW1030
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2014
Lead Product(s) : Pelubiprofen,DW1030
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 25, 2014
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2013
Lead Product(s) : Pelubiprofen,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2013
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 01, 2013
Lead Product(s) : Pelubiprofen,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2013
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2013
Lead Product(s) : Pelubiprofen,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2013
Details:
Undisclosed
Lead Product(s): Pelubiprofen,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 28, 2013
Lead Product(s) : Pelubiprofen,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2013
Market Place
Reply
14 Jan 2020
ABOUT THIS PAGE
47
PharmaCompass offers a list of Pelubiprofen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pelubiprofen manufacturer or Pelubiprofen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pelubiprofen manufacturer or Pelubiprofen supplier.
PharmaCompass also assists you with knowing the Pelubiprofen API Price utilized in the formulation of products. Pelubiprofen API Price is not always fixed or binding as the Pelubiprofen Price is obtained through a variety of data sources. The Pelubiprofen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pelubiprofen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pelubiprofen, including repackagers and relabelers. The FDA regulates Pelubiprofen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pelubiprofen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Pelubiprofen supplier is an individual or a company that provides Pelubiprofen active pharmaceutical ingredient (API) or Pelubiprofen finished formulations upon request. The Pelubiprofen suppliers may include Pelubiprofen API manufacturers, exporters, distributors and traders.
click here to find a list of Pelubiprofen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pelubiprofen Drug Master File in Korea (Pelubiprofen KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pelubiprofen. The MFDS reviews the Pelubiprofen KDMF as part of the drug registration process and uses the information provided in the Pelubiprofen KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pelubiprofen KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pelubiprofen API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pelubiprofen suppliers with KDMF on PharmaCompass.
Pelubiprofen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pelubiprofen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pelubiprofen GMP manufacturer or Pelubiprofen GMP API supplier for your needs.
A Pelubiprofen CoA (Certificate of Analysis) is a formal document that attests to Pelubiprofen's compliance with Pelubiprofen specifications and serves as a tool for batch-level quality control.
Pelubiprofen CoA mostly includes findings from lab analyses of a specific batch. For each Pelubiprofen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pelubiprofen may be tested according to a variety of international standards, such as European Pharmacopoeia (Pelubiprofen EP), Pelubiprofen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pelubiprofen USP).